{"title": "Vacunas de ARN para COVID-19", "author": null, "url": null, "hostname": null, "description": "Vacunas de ARN para COVID-19", "sitename": null, "date": "2020-11-19", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Los recientes anuncios de Pfizer/BioNTech y Moderna sobre los resultados de sus vacunas candidatas para COVID-19 son prometedores. Ambas vacunas de utilizan la misma aproximaci\u00f3n para preparar al organismo ante un eventual contacto con el coronavirus SARS-CoV-2: utilizar ARNs mensajeros sint\u00e9ticos con las instrucciones de una prote\u00edna viral. No obstante, existen diferencias en su composici\u00f3n, as\u00ed como en su mantenimiento y protocolo de administraci\u00f3n. Igualmente, en ambos casos, los ensayos cl\u00ednicos siguen en marcha por lo que los resultados no son los definitivos, y la informaci\u00f3n sobre eficacia y seguridad disponible hasta el momento procede de las notas de prensa emitidas por las empresas.\nLas vacunas de ARN siguen la estrategia de utilizar el ARN, mol\u00e9cula menos permanente que el ADN, como herramienta terap\u00e9utica. Esta aproximaci\u00f3n se basa en que la introducci\u00f3n de un ARN mensajero sint\u00e9tico en una c\u00e9lula la convierte en productora de la prote\u00edna en cuesti\u00f3n. De este modo,si se administra un ARN que codifica para una prote\u00edna terap\u00e9utica para tratar una enfermedad, las propias c\u00e9lulas se convertir\u00e1n en peque\u00f1as f\u00e1bricas de producci\u00f3n del f\u00e1rmaco.\nPese a la sencillez de su planteamiento, el desarrollo de f\u00e1rmacos basados en ARN ha tenido que hacer frente a varios retos para poder llegar a la fase de evaluaci\u00f3n cl\u00ednica. Uno de ellos es que el ARN sint\u00e9tico puede detectarse como un agente extra\u00f1o en las c\u00e9lulas y ser degradado, activando mecanismos inmunitarios que comprometen su objetivo terap\u00e9utico de producir prote\u00edna y pueden representar un riesgo para los posibles pacientes. La resoluci\u00f3n de este problema lleg\u00f3 de la mano de Katalin Karik\u00f3 y Drew Weissman en\n[2005](https://www.cell.com/immunity/fulltext/S1074-7613(05)00211-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761305002116%3Fshowall%3Dtrue) y fue un factor decisivo a favor de la investigaci\u00f3n del [ARN como mol\u00e9cula terap\u00e9utica](https://pubmed.ncbi.nlm.nih.gov/17786850/). Adem\u00e1s impuls\u00f3 la creaci\u00f3n de empresas como Moderna y BioNTech, dirigidas a desarrollar f\u00e1rmacos basados en ARN mensajero. Ambas empresas tienen varios productos en fase de ensayos cl\u00ednicos, pero todav\u00eda no han recibido aprobaci\u00f3n para ninguno.\nAl igual que el resto de vacunas, el objetivo de las vacunas de ARN es prevenir la infecci\u00f3n, entrenando al organismo para que sea capaz de reconocer al organismo infeccioso y actuar frente a \u00e9l en caso de entrar en contacto. Las vacunas de ARN proporcionan a las c\u00e9lulas las instrucciones para producir una prote\u00edna viral que induce una respuesta inmunitaria frente al agente infeccioso concreto y favorece que el organismo genere una memoria inmunitaria que lo proteja en el futuro.\nUna ventaja de este tipo de vacunas es que su dise\u00f1o est\u00e1 basado en el genoma del agente infeccioso, en este caso el coronavirus, y no es necesario trabajar con \u00e9l en el laboratorio. Esta caracter\u00edstica hizo posible que en el momento en el que se obtuvo el genoma del coronavirus SARS-CoV-2, empresas como Moderna o BioNtech comenzaran a desarrollar sus vacunas candidatas. En el caso de Moderna, por ejemplo, el primer lote de vacuna para ser testada a nivel cl\u00ednico fue completado el 7 de febrero, apenas un mes despu\u00e9s de la publicaci\u00f3n del genoma de SARS-CoV-2. La primera inoculaci\u00f3n de esta vacuna a una persona fue el 16 de Marzo.\nLas vacunas dise\u00f1adas por Moderna y BioNTech contienen ARN mensajero que codifica una forma de la prote\u00edna S del coronavirus. Esta prote\u00edna tiene un papel relevante en la entrada del virus a las c\u00e9lulas por lo que dirigir al sistema inmunitario frente a ella es una estrategia general de m\u00faltiples vacunas, m\u00e1s all\u00e1 de las de ARN.\nTanto\n[mRNA-1273](https://clinicaltrials.gov/ct2/show/NCT04283461), la vacuna de Moderna, como [BNT162b2](https://www.drugs.com/history/bnt162b2.html), la vacuna dise\u00f1ada por BioNTech, consisten en una part\u00edcula de l\u00edpidos que contiene en su interior el ARN codificante de una versi\u00f3n estabilizada de la prote\u00edna S. Este ARN contiene dos cambios en la secuencia proteica resultante que llevan a que la prote\u00edna S se encuentre de forma permanente en su conformaci\u00f3n previa a la uni\u00f3n con el receptor, conformaci\u00f3n que es la que refleja mejor la presencia del virus real con el que tendr\u00e1n que interaccionar los anticuerpos neutralizadores generados por el organismo. El ARN codificante que incluye BNT162b2, tiene adem\u00e1s algunos de sus nucle\u00f3sidos modificados, caracter\u00edstica que en estudios previos se ha observado que reduce la degradaci\u00f3n del ARN terap\u00e9utico.\nLa cobertura lip\u00eddica de las vacunas favorece su entrada a las c\u00e9lulas y una vez liberado el ARN en el interior, la propia maquinaria de la c\u00e9lula se encarga de producir la prote\u00edna S.\nTanto la vacuna de Moderna como la de BioNTech requieren dos dosis para inducir protecci\u00f3n. En el caso de Moderna, las dosis est\u00e1n separadas por 28 d\u00edas, mientras que en la vacuna de BioNTech son 21 d\u00edas.\nPara poder hacer frente a las necesidades de producci\u00f3n y distribuci\u00f3n de la vacuna para la COVID-19 BioNTech se ha asociado con la farmac\u00e9utica Pfizer. Moderna realiza sus ensayos cl\u00ednicos en colaboraci\u00f3n con el Instituto Nacional de Alergias y Enfermedades Infecciosas, parte del Instituto Nacional de Salud de EE.UU., y est\u00e1 financiada por la Autoridad de Investigaci\u00f3n y Desarrollo Biom\u00e9dico Avanzado, del Departamento de Salud y Servicios Humanos.\nTanto mRNA-1273 como BNT162b2 han pasado por estudios cl\u00ednicos de fase 1 y fase 2 que hacen una primera valoraci\u00f3n de la seguridad, tolerabilidad y eficacia potencial de las vacunas.\nEn la actualidad, ambas vacunas se encuentran en ensayos cl\u00ednicos de fase 3, que permiten evaluar a mayor escala la eficacia de un f\u00e1rmaco o vacuna. En estos ensayos se inocula la vacuna o un placebo a miles de voluntarios participantes y se espera a que un n\u00famero significativo se infecte de forma natural con el virus. Si la vacuna confiere protecci\u00f3n frente al virus se espera que el n\u00famero de personas que reciben la vacuna y se han contagiado sea significativamente menor que el n\u00famero de personas que reciben el placebo y se infectan. La eficacia en las condiciones del ensayo se estima a partir de cuantos participantes que recibieron placebo se han contagiado respecto a los que recibieron la vacuna, todos ellos haciendo vida normal, con medidas de protecci\u00f3n actuales. Tanto en la vacuna de Pfizer/BioNTech como en el caso de Moderna, la eficacia ha sido evaluada por comit\u00e9s externos a ambos estudios.\nCon los datos disponibles hasta la fecha,\n[Pfizer y BionTech](https://www.businesswire.com/news/home/20201109005539/en/) anunciaron la semana pasada que su vacuna tiene un 90% de eficacia. Estos resultados preliminares derivan de los primeros 94 participantes del ensayo que se han contagiado con coronavirus de forma natural al menos una semana despu\u00e9s de la segunda dosis.\nEn total, el\n[ensayo de Pfizer y BioNTech](https://www.pfizer.com/science/coronavirus) contar\u00e1 con 43.538 participantes, de los que 38 955 han recibido las dos dosis necesarias hasta el momento. Los responsables del estudio han anunciado que realizar\u00e1n un an\u00e1lisis final cuando se alcancen los 164 infectados.\nPor otra parte,\n[Moderna ha anunciado esta semana](https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy) que su vacuna candidata tiene casi un 95% de eficacia, seg\u00fan los primeros resultados de un ensayo con m\u00e1s de 30 000 personas. En este caso, la eficacia ha sido calculada a partir de 95 casos de contagio ocurridos dos semanas tras la segunda dosis de vacuna, 90 correspondientes al grupo placebo y 5 al grupo que recibi\u00f3 la vacuna. En la nota de prensa que acompa\u00f1a al anuncio de Moderna tambi\u00e9n se hace referencia a los primeros datos sobre la protecci\u00f3n de su vacuna frente a los casos m\u00e1s graves de COVID-19: de los 11 casos graves evaluados, todos hab\u00edan recibido el placebo. Moderna tambi\u00e9n indica que la mayor\u00eda de los efectos adversos asociados a la vacuna fueron moderados o leves y en general de corta duraci\u00f3n.\nHasta el momento la informaci\u00f3n sobre la eficacia de ambas vacunas en los ensayos en fase 3 deriva de las notas de prensa presentadas por ambas empresas. Los resultados de las fases de investigaci\u00f3n anteriores fueron publicados en diversas revistas cient\u00edficas y habr\u00e1 que esperar a que se realicen los an\u00e1lisis finales para disponer de informaci\u00f3n m\u00e1s detallada.\nLa vacuna BNT162b2 de Pfizer/BioNTech se sigue evaluando en ensayos en fase 3 en EE.UU., Alemania, Argentina, Brasil, Sud\u00e1frica y otros pa\u00edses. Tambi\u00e9n se\n[ha anunciado](https://www.akm.ru/eng/news/biontech-and-fosun-pharma-receive-approval-to-commence-covid-19-vaccine-candidate-bnt162b2-trial-in-/) la aprobaci\u00f3n para comenzar ensayos de fase 2 en china, en colaboraci\u00f3n con Fosun Pharma. De momento, esta vacuna ha recibido la designaci\u00f3n de \u201cV\u00eda R\u00e1pida\u201d de la Administraci\u00f3n de Medicamentos y Alimentos de EEUU y se [ha iniciado](https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-and-pfizer-initiate-rolling-submission-european) el proceso de solicitud para la Agencia Europea del Medicamento.\nAlbert Bourla, presidente y consejero delegado (CEO) de Pfizer,\n[ha se\u00f1alado](https://www.pfizer.com/news/hot-topics/albert_bourla_discusses_covid_19_vaccine_efficacy_results) que esperar\u00e1n a tener los datos de seguridad de la vacuna correspondientes a una mediana de dos meses tras la segunda dosis de vacuna para solicitar la Autorizaci\u00f3n de Uso de Emergencia de la FDA. Seg\u00fan sus estimaciones esto ser\u00e1 alrededor de la tercera semana de noviembre. \u201cEficacia, seguridad y producci\u00f3n consistente son los tres requisitos que son necesarios antes de ser capaces de solicitar la autorizaci\u00f3n\u201d, indica Bourla en la p\u00e1gina web de Pfizer.\nLa vacuna mRNA-1273 de Moderna se est\u00e1 evaluando en ensayos de fase 3 en EE.UU. La nota de prensa de Moderna indica que ante los resultados obtenidos se solicitar\u00e1 una Autorizaci\u00f3n de Uso de Emergencia por parte de la FDA en las pr\u00f3ximas semanas. Tambi\u00e9n se enviar\u00e1n solicitudes a otras agencias reguladoras, incluyendo la Agencia Europea del Medicamento.\nLos resultados preliminares de ambas vacunas son positivos y muy prometedores, especialmente, si se tiene en cuenta que las dos vacunas se est\u00e1n evaluando en personas de varios grupos de edad y comunidades diversas. No obstante, quedan todav\u00eda algunas cuestiones por resolver.\nLo primero de todo ser\u00e1 completar los ensayos cl\u00ednicos en marcha, para obtener la informaci\u00f3n m\u00e1s completa posible sobre la seguridad, eficacia y efectos de las vacunas.\nPor ejemplo, un aspecto a estudiar el efecto a largo plazo de ambas vacunas en el organismo, tanto a nivel de producci\u00f3n continuada de prote\u00edna S como a nivel de protecci\u00f3n frente a la infecci\u00f3n. Una de las ventajas para plantear la utilizaci\u00f3n de ARN terap\u00e9utico, m\u00e1s all\u00e1 de las vacunas, es que se trata de una mol\u00e9cula menos estable y no modifica el ADN de las c\u00e9lulas, aunque s\u00ed produzca una respuesta en el interior de la c\u00e9lula. Hasta el momento no hay datos de durante cu\u00e1nto tiempo se produce prote\u00edna viral tras la administraci\u00f3n de las vacunas de ARN o de la duraci\u00f3n de la protecci\u00f3n inducida, lo que deber\u00e1 ser investigado en los participantes de los ensayos.\nOtra cuesti\u00f3n interesante relativa a cualquier vacuna que se plantee para COVID-19 es c\u00f3mo se producir\u00e1n, mantendr\u00e1n y distribuir\u00e1n a gran escala las dosis de vacunas necesarias para hacer frente a la pandemia.\nRespecto a la producci\u00f3n, tanto Pfizer/BioNTech como Moderna se\u00f1alan que esperan producir aproximadamente 20 millones de dosis para finales de 2020. Las cifras de producci\u00f3n para 2021 podr\u00edan alcanzar los 1000 millones de dosis en el caso de Moderna y 1300 millones en el caso de Pfizer/BioNTech. Teniendo en cuenta la necesidad de dos dosis por persona, potencialmente podr\u00eda vacunarse a alrededor de 1000 millones de personas entre ambas vacunas. Diversos pa\u00edses han iniciado acuerdos para obtener vacunas.\nEn cuanto a la distribuci\u00f3n y almacenamiento, la vacuna de Moderna ofrece ciertas ventajas sobre la de Pfizer, ya que es estable a temperatura ambiente durante 12 horas, suficiente para plantear una vacunaci\u00f3n en diferentes localizaciones, y puede mantenerse en nevera (a 2-8\u00baC) durante 30 d\u00edas, lo que favorece su almacenamiento en centros de salud. Para el env\u00edo y acumulaci\u00f3n a gran escala la vacuna se mantiene estable a temperaturas de -20\u00baC, correspondientes a un congelador com\u00fan, durante 6 meses. La vacuna de Pfizer/BioNTech requiere temperaturas de -70\u00baC para su almacenamiento, lo que puede representar un problema grave para su distribuci\u00f3n.\nLa situaci\u00f3n de urgencia impuesta por la pandemia de COVID-19, que ya se ha cobrado m\u00e1s de un mill\u00f3n de muertes en todo el mundo, ha acelerado la maquinaria de dise\u00f1o y producci\u00f3n de vacunas de tal forma que, en apenas un a\u00f1o ya se dispone de varias candidatas con gran potencial. Si los resultados de las vacunas de Pfizer/BioNTech y Moderna en cuanto a seguridad y eficacia se mantienen, su repercusi\u00f3n ir\u00e1 m\u00e1s all\u00e1 del gran logro que supondr\u00eda poner un freno a la pandemia. La aprobaci\u00f3n de cualquiera de las dos vacunas, representar\u00eda la primera aprobaci\u00f3n de un f\u00e1rmaco basado en ARN mensajero y confirmar\u00eda las expectativas del potencial del ARN mensajero como herramienta terap\u00e9utica que llevan a\u00f1os impulsando a diferentes equipos de investigaci\u00f3n.\nACTUALIZACI\u00d3N 19-11-2020: Pfizer/BioNTech\n[anunciaron el 18 de noviembre](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine) que la vacuna alcanza el 95% de eficacia, a partir de datos obtenidos de los primeros 170 participantes del ensayo confirmados como positivos para el coronavirus SARS-CoV-2. 162 de los casos ocurrieron entre personas que hab\u00edan recibido el placebo. Los 8 restantes ocurrieron en personas que hab\u00edan recibido la vacuna. La nota de prensa donde se ha anunciado comunica tambi\u00e9n que de 10 casos de COVID-19 graves, 9 ocurrieron en personas que hab\u00edan recibido el placebo.\nFuentes:\nModerna\u2019s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study.\n[https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy](https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy)\nPfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study.\n[https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against)\nA Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals.\n[https://www.pfizer.com/science/coronavirus](https://www.pfizer.com/science/coronavirus)\nBioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2.\n[https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-and-pfizer-initiate-rolling-submission-european](https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-and-pfizer-initiate-rolling-submission-european)\nArt\u00edculos cient\u00edficos de ensayos de fase 1 o 2 de las vacunas:\nWalsh EE, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 Oct 14:NEJMoa2027906. doi: 10.1056/NEJMoa2027906.\nAnderson EJ, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Sep 29:NEJMoa2028436. doi: 10.1056/NEJMoa2028436.", "language": null, "image": null, "pagetype": null, "links": ["http://biotech-spain.com/en/", null, "http://biotech-spain.com/en/", "http://biotech-spain.com/en/articles", "http://biotech-spain.com/en/directory", "http://biotech-spain.com/en/admin/", "http://biotech-spain.com/en/contact", "/en", "/es", "https://www.facebook.com/biotech.in.spain", "https://twitter.com/Biotech_Spain", "https://plus.google.com/+Biotechspain-Biotecnolog\u00eda-en-Espa\u00f1a", "https://www.linkedin.com/company/biotech-spain/", "http://biotech-spain.com/en/", "http://biotech-spain.com/en/articles", "http://biotech-spain.com/en/articles?category=biodrugs", "http://biotech-spain.com/en/articles?category=cellular-and-molecular-b", "http://biotech-spain.com/en/articles?category=research-centers", "http://biotech-spain.com/en/articles?category=communication-media", "http://biotech-spain.com/en/articles?category=drug-development", "http://biotech-spain.com/en/articles?category=clinical-trials", "http://biotech-spain.com/en/articles?category=epidemiology", "http://biotech-spain.com/en/articles?category=genomics", "http://biotech-spain.com/en/articles?category=infections", "http://biotech-spain.com/en/articles?category=sales-marketing", "http://biotech-spain.com/en/articles?category=othe", "http://biotech-spain.com/en/articles?category=proteins", "http://biotech-spain.com/en/articles?category=proteomics", "http://biotech-spain.com/en/articles?category=scientific-publications", "http://biotech-spain.com/en/articles?category=research-network", "http://biotech-spain.com/en/articles?category=research-services-and-supp", "http://biotech-spain.com/en/articles?category=vaccines", "http://biotech-spain.com/en/articles/vacunas-de-arn-para-covid-19/", "https://www.cell.com/immunity/fulltext/S1074-7613(05)00211-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761305002116%3Fshowall%3Dtrue", "https://pubmed.ncbi.nlm.nih.gov/17786850/", "https://clinicaltrials.gov/ct2/show/NCT04283461", "https://www.drugs.com/history/bnt162b2.html", "https://www.businesswire.com/news/home/20201109005539/en/", "https://www.pfizer.com/science/coronavirus", "https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy", "https://www.akm.ru/eng/news/biontech-and-fosun-pharma-receive-approval-to-commence-covid-19-vaccine-candidate-bnt162b2-trial-in-/", "https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-and-pfizer-initiate-rolling-submission-european", "https://www.pfizer.com/news/hot-topics/albert_bourla_discusses_covid_19_vaccine_efficacy_results", "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine", "https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy", "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against", "https://www.pfizer.com/science/coronavirus", "https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-and-pfizer-initiate-rolling-submission-european", "http://biotech-spain.com/en/directory/revista+gen%c3%a9tica+m%c3%a9dica/", "http://biotech-spain.com/en/articles/tags/respuesta+inmunitaria", "http://biotech-spain.com/en/articles/tags/vacuna", "http://biotech-spain.com/en/articles/tags/covid-19", "http://biotech-spain.com/en/articles/tags/arn", "http://biotech-spain.com/en/articles/tags/moderna", "http://biotech-spain.com/en/articles/tags/biontech", "http://biotech-spain.com/en/articles/tags/pfizer", "https://genotipia.com/genetica_medica_news/vacunas-de-arn-covid-19/", "http://biotech-spain.com/en/admin/login", "http://biotech-spain.com/en/admin/login", "http://biotech-spain.com/en/articles/el-diagn-stico-gen-tico-neonatal-mejora-la-esperanza-de-vida-de-ni-os-con-una-inmunodeficiencia-letal/", "http://biotech-spain.com/en/articles/m-s-de-1-500-cambios-epigen-ticos-en-el-esperma-asociados-a-la-edad-paterna/", "http://biotech-spain.com/en/articles/tuneable-reverse-photochromes-in-the-solid-state-/", "#tab-1", "#tab-2", "http://biotech-spain.com/en/articles/eosin-filos-qu-significa-tener-valores-altos-o-bajos-/", "http://biotech-spain.com/en/articles/tiny-sea-creatures-reveal-the-ancient-origins-of-neurons/", "http://biotech-spain.com/en/articles/tiny-sea-creatures-reveal-the-ancient-origins-of-neurons/", "http://biotech-spain.com/en/articles/los-pacientes-con-psoriasis-grave-tienen-mayor-riesgo-cardiovascular/", "http://biotech-spain.com/en/articles/las-pruebas-moleculares-permiten-detectar-de-forma-m-s-eficaz-el-c-ncer-de-endometrio-y-evitar-histerectom-as-innecesarias-en-mujeres-con-sangrado-post-menop-usico/", "http://biotech-spain.com/en/articles/a-study-by-ibs-granada-reveals-that-exposure-to-perfluorinated-compounds-pfas-affects-the-reproductive-health-of-adolescents/", "http://biotech-spain.com/en/articles/key-protein-identified-in-fat-function-and-obesity-related-problems/", "http://biotech-spain.com/en/articles/incliva-y-uv-investigan-la-p-rdida-de-conectividad-entre-el-hipocampo-izquierdo-y-derecho-en-la-enfermedad-de-alzheimer/", "http://biotech-spain.com/en/articles/vhio-led-retrospective-study-evaluates-the-clinical-and-genomic-features-of-early-onset-pancreatic-cancer-/", "http://biotech-spain.com/en/articles/a-portable-sensor-could-detect-cancerous-tumors/", "http://biotech-spain.com/en/articles/tags/cancer", "http://biotech-spain.com/en/articles/tags/covid-19", "http://biotech-spain.com/en/articles/tags/alzheimer", "http://biotech-spain.com/en/articles/tags/investigaci%c3%b3n", "http://biotech-spain.com/en/articles/tags/salud", "http://biotech-spain.com/en/articles/tags/coronavirus", "http://biotech-spain.com/en/articles/tags/covid19", "http://biotech-spain.com/en/terms", "http://biotech-spain.com/en/privacy", "https://www.facebook.com/biotech.in.spain", "https://twitter.com/Biotech_Spain", "https://plus.google.com/+Biotechspain-Biotecnolog\u00eda-en-Espa\u00f1a", "https://www.linkedin.com/company/biotech-spain/", "http://biotech-spain.com/en/articles?category=substance-abuse", "http://biotech-spain.com/en/articles?category=agrobiotechnology", "http://biotech-spain.com/en/articles?category=food-sub", "http://biotech-spain.com/en/articles?category=animal-food-feed", "http://biotech-spain.com/en/articles?category=functional-food", "http://biotech-spain.com/en/articles?category=analgesia-pain", "http://biotech-spain.com/en/articles?category=associations", "http://biotech-spain.com/en/articles?category=biobanks", "http://biotech-spain.com/en/articles?category=bioclusters", "http://biotech-spain.com/en/articles?category=biofuels", "http://biotech-spain.com/en/articles?category=biodrugs", "http://biotech-spain.com/en/articles?category=bioinformatics", "http://biotech-spain.com/en/articles?category=cellular-and-molecular-b", "http://biotech-spain.com/en/articles?category=systems-biology", "http://biotech-spain.com/en/articles?category=evolutionary-biology", "http://biotech-spain.com/en/articles?category=synthetic-biology", "http://biotech-spain.com/en/articles?category=biomarkers", "http://biotech-spain.com/en/articles?category=biomaterials", "http://biotech-spain.com/en/articles?category=marine-based-biotechnology", "http://biotech-spain.com/en/articles?category=business-angels", "http://biotech-spain.com/en/articles?category=cancer", "http://biotech-spain.com/en/articles?category=stem-cells", "http://biotech-spain.com/en/articles?category=cardiovascular-and-cir", "http://biotech-spain.com/en/articles?category=research-centers", "http://biotech-spain.com/en/articles?category=private-clinic", "http://biotech-spain.com/en/articles?category=communication-media", "http://biotech-spain.com/en/articles?category=consultancy", "http://biotech-spain.com/en/articles?category=biologic-control-plagues-", "http://biotech-spain.com/en/articles?category=quality-control", "http://biotech-spain.com/en/articles?category=corporate-investor", "http://biotech-spain.com/en/articles?category=cosmetics", "http://biotech-spain.com/en/articles?category=cell-culture", "http://biotech-spain.com/en/articles?category=gm-crops", "http://biotech-spain.com/en/articles?category=biological-defense", "http://biotech-spain.com/en/articles?category=dental", "http://biotech-spain.com/en/articles?category=dermatology", "http://biotech-spain.com/en/articles?category=muskuloskeletal", "http://biotech-spain.com/en/articles?category=biotechnology-kits", "http://biotech-spain.com/en/articles?category=software-development", "http://biotech-spain.com/en/articles?category=diagnostic-imaging", "http://biotech-spain.com/en/articles?category=medical-devices", "http://biotech-spain.com/en/articles?category=drug-delivery", "http://biotech-spain.com/en/articles?category=drug-development", "http://biotech-spain.com/en/articles?category=drug-discovery", "http://biotech-spain.com/en/articles?category=pregnancy-reproduction", "http://biotech-spain.com/en/articles?category=venture-capital-manageme", "http://biotech-spain.com/en/articles?category=energy", "http://biotech-spain.com/en/articles?category=bone-diseases", "http://biotech-spain.com/en/articles?category=chronic-diseases", "http://biotech-spain.com/en/articles?category=degenerative-diseases", "http://biotech-spain.com/en/articles?category=genetic-diseases", "http://biotech-spain.com/en/articles?category=hereditary-diseases", "http://biotech-spain.com/en/articles?category=inflamatory-diseases", "http://biotech-spain.com/en/articles?category=neurologic-diseases", "http://biotech-spain.com/en/articles?category=rares-diseases", "http://biotech-spain.com/en/articles?category=clinical-trials", "http://biotech-spain.com/en/articles?category=public-entity", "http://biotech-spain.com/en/articles?category=epidemiology", "http://biotech-spain.com/en/articles?category=epigenetics", "http://biotech-spain.com/en/articles?category=medical-and-surgica", "http://biotech-spain.com/en/articles?category=patient-monito", "http://biotech-spain.com/en/articles?category=manufacture-of-biotech", "http://biotech-spain.com/en/articles?category=manufacter-of-resins-to-purifi", "http://biotech-spain.com/en/articles?category=manufacture-and-commercialization-of-fermentation-or-biocatalysis", "http://biotech-spain.com/en/articles?category=manufacture-and-commercialization-of-enzymes-", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=manufacture-o", "http://biotech-spain.com/en/articles?category=manufa", "http://biotech-spain.com/en/articles?category=pharmacy", "http://biotech-spain.com/en/articles?category=pharmacogenomics", "http://biotech-spain.com/en/articles?category=public-financing", "http://biotech-spain.com/en/articles?category=investment-funds", "http://biotech-spain.com/en/articles?category=training", "http://biotech-spain.com/en/articles?category=foundatio", "http://biotech-spain.com/en/articles?category=foundation", "http://biotech-spain.com/en/articles?category=genomics", "http://biotech-spain.com/en/articles?category=hospitals", "http://biotech-spain.com/en/articles?category=infections", "http://biotech-spain.com/en/articles?category=engineering", "http://biotech-spain.com/en/articles?category=immunology", "http://biotech-spain.com/en/articles?category=healthcare-facilities-and", "http://biotech-spain.com/en/articles?category=scientific-t", "http://biotech-spain.com/en/articles?category=inter", "http://biotech-spain.com/en/articles?category=institutional-investor", "http://biotech-spain.com/en/articles?category=private-investor", "http://biotech-spain.com/en/articles?category=leasing", "http://biotech-spain.com/en/articles?category=environmental-cleanup-testing", "http://biotech-spain.com/en/articles?category=maintenance-cell-culture", "http://biotech-spain.com/en/articles?category=sales-marketing", "http://biotech-spain.com/en/articles?category=environment", "http://biotech-spain.com/en/articles?category=metabolomics", "http://biotech-spain.com/en/articles?category=microbiology", "http://biotech-spain.com/en/articles?category=nanotechnology", "http://biotech-spain.com/en/articles?category=neuroscience", "http://biotech-spain.com/en/articles?category=nutrition", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=oftalmology", "http://biotech-spain.com/en/articles?category=cost-optimization", "http://biotech-spain.com/en/articles?category=othe", "http://biotech-spain.com/en/articles?category=peptides", "http://biotech-spain.com/en/articles?category=science-tec", "http://biotech-spain.com/en/articles?category=probiotics", "http://biotech-spain.com/en/articles?category=blood-products", "http://biotech-spain.com/en/articles?category=disposable-medical-prod", "http://biotech-spain.com/en/articles?category=industrial-property-p", "http://biotech-spain.com/en/articles?category=proteins", "http://biotech-spain.com/en/articles?category=proteomics", "http://biotech-spain.com/en/articles?category=dna-tests", "http://biotech-spain.com/en/articles?category=diagnostic-tests", "http://biotech-spain.com/en/articles?category=scientific-publications", "http://biotech-spain.com/en/articles?category=chemistry", "http://biotech-spain.com/en/articles?category=human-resources", "http://biotech-spain.com/en/articles?category=research-network", "http://biotech-spain.com/en/articles?category=r", "http://biotech-spain.com/en/articles?category=animal-health", "http://biotech-spain.com/en/articles?category=women-s-health", "http://biotech-spain.com/en/articles?category=child-health", "http://biotech-spain.com/en/articles?category=mental-health", "http://biotech-spain.com/en/articles?category=senior-health", "http://biotech-spain.com/en/articles?category=healthy", "http://biotech-spain.com/en/articles?category=blood-and-lymphatic-system", "http://biotech-spain.com/en/articles?category=screening", "http://biotech-spain.com/en/articles?category=food-safety", "http://biotech-spain.com/en/articles?category=cro-cmo-services", "http://biotech-spain.com/en/articles?category=research-services-and-supp", "http://biotech-spain.com/en/articles?category=legal-services", "http://biotech-spain.com/en/articles?category=auditory-system", "http://biotech-spain.com/en/articles?category=digestive-system", "http://biotech-spain.com/en/articles?category=kidney-and-geni", "http://biotech-spain.com/en/articles?category=locomotive-system", "http://biotech-spain.com/en/articles?category=metabolic-sy", "http://biotech-spain.com/en/articles?category=central-nervous-system", "http://biotech-spain.com/en/articles?category=respiratory-and-pulmonary-sy", "http://biotech-spain.com/en/articles?category=laser-optical-systems", "http://biotech-spain.com/en/articles?category=cellular-therapy", "http://biotech-spain.com/en/articles?category=gene-therapy", "http://biotech-spain.com/en/articles?category=tissue-therapy", "http://biotech-spain.com/en/articles?category=toxicology", "http://biotech-spain.com/en/articles?category=technology-transfer", "http://biotech-spain.com/en/articles?category=transplant", "http://biotech-spain.com/en/articles?category=universities", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=vaccines", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=venture-capital", "http://biotech-spain.com/en/articles?category=vitamins-and-nutri", "http://biotech-spain.com/en/articles?category=viral-vector", "http://biotech-spain.com/en/directory?category=substance-abuse", "http://biotech-spain.com/en/directory?category=agrobiotechnology", "http://biotech-spain.com/en/directory?category=food-sub", "http://biotech-spain.com/en/directory?category=animal-food-feed", "http://biotech-spain.com/en/directory?category=functional-food", "http://biotech-spain.com/en/directory?category=analgesia-pain", "http://biotech-spain.com/en/directory?category=associations", "http://biotech-spain.com/en/directory?category=biobanks", "http://biotech-spain.com/en/directory?category=bioclusters", "http://biotech-spain.com/en/directory?category=biofuels", "http://biotech-spain.com/en/directory?category=biodrugs", "http://biotech-spain.com/en/directory?category=bioinformatics", "http://biotech-spain.com/en/directory?category=cellular-and-molecular-b", "http://biotech-spain.com/en/directory?category=systems-biology", "http://biotech-spain.com/en/directory?category=evolutionary-biology", "http://biotech-spain.com/en/directory?category=synthetic-biology", "http://biotech-spain.com/en/directory?category=biomarkers", "http://biotech-spain.com/en/directory?category=biomaterials", "http://biotech-spain.com/en/directory?category=marine-based-biotechnology", "http://biotech-spain.com/en/directory?category=business-angels", "http://biotech-spain.com/en/directory?category=cancer", "http://biotech-spain.com/en/directory?category=stem-cells", "http://biotech-spain.com/en/directory?category=cardiovascular-and-cir", "http://biotech-spain.com/en/directory?category=research-centers", "http://biotech-spain.com/en/directory?category=private-clinic", "http://biotech-spain.com/en/directory?category=communication-media", "http://biotech-spain.com/en/directory?category=consultancy", "http://biotech-spain.com/en/directory?category=biologic-control-plagues-", "http://biotech-spain.com/en/directory?category=quality-control", "http://biotech-spain.com/en/directory?category=corporate-investor", "http://biotech-spain.com/en/directory?category=cosmetics", "http://biotech-spain.com/en/directory?category=cell-culture", "http://biotech-spain.com/en/directory?category=gm-crops", "http://biotech-spain.com/en/directory?category=biological-defense", "http://biotech-spain.com/en/directory?category=dental", "http://biotech-spain.com/en/directory?category=dermatology", "http://biotech-spain.com/en/directory?category=muskuloskeletal", "http://biotech-spain.com/en/directory?category=biotechnology-kits", "http://biotech-spain.com/en/directory?category=software-development", "http://biotech-spain.com/en/directory?category=diagnostic-imaging", "http://biotech-spain.com/en/directory?category=medical-devices", "http://biotech-spain.com/en/directory?category=drug-delivery", "http://biotech-spain.com/en/directory?category=drug-development", "http://biotech-spain.com/en/directory?category=drug-discovery", "http://biotech-spain.com/en/directory?category=pregnancy-reproduction", "http://biotech-spain.com/en/directory?category=venture-capital-manageme", "http://biotech-spain.com/en/directory?category=energy", "http://biotech-spain.com/en/directory?category=bone-diseases", "http://biotech-spain.com/en/directory?category=chronic-diseases", "http://biotech-spain.com/en/directory?category=degenerative-diseases", "http://biotech-spain.com/en/directory?category=genetic-diseases", "http://biotech-spain.com/en/directory?category=hereditary-diseases", "http://biotech-spain.com/en/directory?category=inflamatory-diseases", "http://biotech-spain.com/en/directory?category=neurologic-diseases", "http://biotech-spain.com/en/directory?category=rares-diseases", "http://biotech-spain.com/en/directory?category=clinical-trials", "http://biotech-spain.com/en/directory?category=public-entity", "http://biotech-spain.com/en/directory?category=epidemiology", "http://biotech-spain.com/en/directory?category=epigenetics", "http://biotech-spain.com/en/directory?category=medical-and-surgica", "http://biotech-spain.com/en/directory?category=patient-monito", "http://biotech-spain.com/en/directory?category=manufacture-of-biotech", "http://biotech-spain.com/en/directory?category=manufacter-of-resins-to-purifi", "http://biotech-spain.com/en/directory?category=manufacture-and-commercialization-of-fermentation-or-biocatalysis", "http://biotech-spain.com/en/directory?category=manufacture-and-commercialization-of-enzymes-", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=manufacture-o", "http://biotech-spain.com/en/directory?category=manufa", "http://biotech-spain.com/en/directory?category=pharmacy", "http://biotech-spain.com/en/directory?category=pharmacogenomics", "http://biotech-spain.com/en/directory?category=public-financing", "http://biotech-spain.com/en/directory?category=investment-funds", "http://biotech-spain.com/en/directory?category=training", "http://biotech-spain.com/en/directory?category=foundatio", "http://biotech-spain.com/en/directory?category=foundation", "http://biotech-spain.com/en/directory?category=genomics", "http://biotech-spain.com/en/directory?category=hospitals", "http://biotech-spain.com/en/directory?category=infections", "http://biotech-spain.com/en/directory?category=engineering", "http://biotech-spain.com/en/directory?category=immunology", "http://biotech-spain.com/en/directory?category=healthcare-facilities-and", "http://biotech-spain.com/en/directory?category=scientific-t", "http://biotech-spain.com/en/directory?category=inter", "http://biotech-spain.com/en/directory?category=institutional-investor", "http://biotech-spain.com/en/directory?category=private-investor", "http://biotech-spain.com/en/directory?category=leasing", "http://biotech-spain.com/en/directory?category=environmental-cleanup-testing", "http://biotech-spain.com/en/directory?category=maintenance-cell-culture", "http://biotech-spain.com/en/directory?category=sales-marketing", "http://biotech-spain.com/en/directory?category=environment", "http://biotech-spain.com/en/directory?category=metabolomics", "http://biotech-spain.com/en/directory?category=microbiology", "http://biotech-spain.com/en/directory?category=nanotechnology", "http://biotech-spain.com/en/directory?category=neuroscience", "http://biotech-spain.com/en/directory?category=nutrition", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=oftalmology", "http://biotech-spain.com/en/directory?category=cost-optimization", "http://biotech-spain.com/en/directory?category=othe", "http://biotech-spain.com/en/directory?category=peptides", "http://biotech-spain.com/en/directory?category=science-tec", "http://biotech-spain.com/en/directory?category=probiotics", "http://biotech-spain.com/en/directory?category=blood-products", "http://biotech-spain.com/en/directory?category=disposable-medical-prod", "http://biotech-spain.com/en/directory?category=industrial-property-p", "http://biotech-spain.com/en/directory?category=proteins", "http://biotech-spain.com/en/directory?category=proteomics", "http://biotech-spain.com/en/directory?category=dna-tests", "http://biotech-spain.com/en/directory?category=diagnostic-tests", "http://biotech-spain.com/en/directory?category=scientific-publications", "http://biotech-spain.com/en/directory?category=chemistry", "http://biotech-spain.com/en/directory?category=human-resources", "http://biotech-spain.com/en/directory?category=research-network", "http://biotech-spain.com/en/directory?category=r", "http://biotech-spain.com/en/directory?category=animal-health", "http://biotech-spain.com/en/directory?category=women-s-health", "http://biotech-spain.com/en/directory?category=child-health", "http://biotech-spain.com/en/directory?category=mental-health", "http://biotech-spain.com/en/directory?category=senior-health", "http://biotech-spain.com/en/directory?category=healthy", "http://biotech-spain.com/en/directory?category=blood-and-lymphatic-system", "http://biotech-spain.com/en/directory?category=screening", "http://biotech-spain.com/en/directory?category=food-safety", "http://biotech-spain.com/en/directory?category=cro-cmo-services", "http://biotech-spain.com/en/directory?category=research-services-and-supp", "http://biotech-spain.com/en/directory?category=legal-services", "http://biotech-spain.com/en/directory?category=auditory-system", "http://biotech-spain.com/en/directory?category=digestive-system", "http://biotech-spain.com/en/directory?category=kidney-and-geni", "http://biotech-spain.com/en/directory?category=locomotive-system", "http://biotech-spain.com/en/directory?category=metabolic-sy", "http://biotech-spain.com/en/directory?category=central-nervous-system", "http://biotech-spain.com/en/directory?category=respiratory-and-pulmonary-sy", "http://biotech-spain.com/en/directory?category=laser-optical-systems", "http://biotech-spain.com/en/directory?category=cellular-therapy", "http://biotech-spain.com/en/directory?category=gene-therapy", "http://biotech-spain.com/en/directory?category=tissue-therapy", "http://biotech-spain.com/en/directory?category=toxicology", "http://biotech-spain.com/en/directory?category=technology-transfer", "http://biotech-spain.com/en/directory?category=transplant", "http://biotech-spain.com/en/directory?category=universities", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=vaccines", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=venture-capital", "http://biotech-spain.com/en/directory?category=vitamins-and-nutri", "http://biotech-spain.com/en/directory?category=viral-vector"]}